TasP using ART regimen as per Benin guidelines + PrEP using Truvada
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Adherence to Medication Regime
Conditions
Adherence to Medication Regime
Trial Timeline
Oct 1, 2014 → Dec 1, 2016
NCT ID
NCT02237027About TasP using ART regimen as per Benin guidelines + PrEP using Truvada
TasP using ART regimen as per Benin guidelines + PrEP using Truvada is a approved stage product being developed by Gilead Sciences for Adherence to Medication Regime. The current trial status is completed. This product is registered under clinical trial identifier NCT02237027. Target conditions include Adherence to Medication Regime.
What happened to similar drugs?
3 of 4 similar drugs in Adherence to Medication Regime were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02237027 | Approved | Completed |
Competing Products
4 competing products in Adherence to Medication Regime
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Advagraf + Prograf | Astellas Pharma | Approved | 39 |
| Tacrolimus BID + Advagraf QD | Astellas Pharma | Phase 3 | 36 |
| Vitamin D Supplement | Gilead Sciences | Approved | 43 |
| ziprasidone | Pfizer | Approved | 43 |